| Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial N Shaverdian, AE Lisberg, K Bornazyan, D Veruttipong, JW Goldman, ... The lancet oncology 18 (7), 895-903, 2017 | 1013 | 2017 |
| 68Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng/mL: impact on salvage … J Calais, J Czernin, M Cao, AU Kishan, JV Hegde, N Shaverdian, ... Journal of Nuclear Medicine 59 (2), 230-237, 2018 | 267 | 2018 |
| Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer AU Kishan, A Dang, AJ Katz, CA Mantz, SP Collins, N Aghdam, FI Chu, ... JAMA network open 2 (2), e188006-e188006, 2019 | 259 | 2019 |
| A synthetic adjuvant to enhance and expand immune responses to influenza vaccines RN Coler, SL Baldwin, N Shaverdian, S Bertholet, SJ Reed, VS Raman, ... PloS one 5 (10), e13677, 2010 | 171 | 2010 |
| A multi-institutional experience of MR-guided liver stereotactic body radiation therapy SA Rosenberg, LE Henke, N Shaverdian, K Mittauer, AP Wojcieszynski, ... Advances in radiation oncology 4 (1), 142-149, 2019 | 136 | 2019 |
| Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations RC Anderson, CB Fox, TS Dutill, N Shaverdian, TL Evers, GR Poshusta, ... Colloids and Surfaces B: Biointerfaces 75 (1), 123-132, 2010 | 122 | 2010 |
| Online adaptive radiation therapy: implementation of a new process of care J Lamb, M Cao, A Kishan, N Agazaryan, DH Thomas, N Shaverdian, ... Cureus 9 (8), 2017 | 120 | 2017 |
| Enhanced humoral and Type 1 cellular immune responses with Fluzone® adjuvanted with a synthetic TLR4 agonist formulated in an emulsion SL Baldwin, N Shaverdian, Y Goto, MS Duthie, VS Raman, T Evers, ... Vaccine 27 (43), 5956-5963, 2009 | 119 | 2009 |
| MyD88 and TRIF synergistic interaction is required for TH1‐cell polarization with a synthetic TLR4 agonist adjuvant MT Orr, MS Duthie, HP Windish, EA Lucas, JA Guderian, TE Hudson, ... European journal of immunology 43 (9), 2398-2408, 2013 | 96 | 2013 |
| Truthfulness in patient-reported outcomes: factors affecting patients’ responses and impact on data quality EM Chang, EF Gillespie, N Shaverdian Patient related outcome measures, 171-186, 2019 | 93 | 2019 |
| Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center A Lisberg, DA Tucker, JW Goldman, B Wolf, J Carroll, A Hardy, K Morris, ... Cancer immunology research 6 (3), 288-294, 2018 | 80* | 2018 |
| Potential impact of 68Ga-PSMA-11 PET/CT on the planning of definitive radiation therapy for prostate cancer J Calais, AU Kishan, M Cao, WP Fendler, M Eiber, K Herrmann, F Ceci, ... Journal of Nuclear Medicine 59 (11), 1714-1721, 2018 | 76 | 2018 |
| Impact of telemedicine on patient satisfaction and perceptions of care quality in radiation oncology N Shaverdian, EF Gillespie, E Cha, SY Kim, S Benvengo, F Chino, ... Journal of the National Comprehensive Cancer Network 19 (10), 1174-1180, 2021 | 74 | 2021 |
| Pretreatment immune parameters predict for overall survival and toxicity in early-stage non–small-cell lung cancer patients treated with stereotactic body radiation therapy N Shaverdian, D Veruttipong, J Wang, D Schaue, P Kupelian, P Lee Clinical lung cancer 17 (1), 39-46, 2016 | 74 | 2016 |
| Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer N Shaverdian, V Gondi, KL Sklenar, EF Dunn, DG Petereit, MR Straub, ... International Journal of Radiation Oncology* Biology* Physics 86 (3), 562-568, 2013 | 67 | 2013 |
| Consolidative use of radiotherapy to block (CURB) oligoprogression―interim analysis of the first randomized study of stereotactic body radiotherapy in patients with … CJ Tsai, JT Yang, DM Guttmann, N Shaverdian, AF Shepherd, J Eng, ... International Journal of Radiation Oncology* Biology* Physics 111 (5), 1325-1326, 2021 | 65 | 2021 |
| Feasibility evaluation of diffusion-weighted imaging using an integrated MRI-radiotherapy system for response assessment to neoadjuvant therapy in rectal cancer N Shaverdian, Y Yang, P Hu, S Hart, K Sheng, J Lamb, M Cao, ... The British journal of radiology 90 (1071), 20160739, 2017 | 55 | 2017 |
| Clinical outcomes, local–regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab M Offin, N Shaverdian, A Rimner, S Lobaugh, AF Shepherd, CB Simone II, ... Radiotherapy and Oncology 149, 205-211, 2020 | 49 | 2020 |
| The patient's perspective on breast radiotherapy: initial fears and expectations versus reality N Shaverdian, X Wang, JV Hegde, C Aledia, JB Weidhaas, ML Steinberg, ... Cancer 124 (8), 1673-1681, 2018 | 44 | 2018 |
| Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab N Shaverdian, M Thor, AF Shepherd, MD Offin, A Jackson, AJ Wu, ... Cancer Medicine 9 (13), 4622-4631, 2020 | 43 | 2020 |
